Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04165564 · ClinicalTrials.gov registry record
DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
A clinical trial of Pulmonary Disease, sponsored by Boston University.
- Active
- Registry status
- 85
- Enrollment target
- 19
- Study locations
NCT04165564: Active study of Pulmonary Disease, sponsored by Boston University.
NCT04165564 is a study of Pulmonary Disease that is active but no longer recruiting, run by Boston University. The registered enrollment target is 85 participants, below the 620-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (86% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04165564, a study of Pulmonary Disease, is active but no longer recruiting, sponsored by Boston University.
- ACTIVE NOT RECRUITING
- Registry status
- 85 participants
- Enrollment target
- 19
- Study locations
Study Summary
DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.
Primary Outcome
The number of new cases of lung cancer that developed divided by the population at risk.
Conditions Studied
Interventions
- OTHER Institutional standard of care
- OTHER Biosamples of airway and blood
Study Locations (19)
Pennsylvania
- American College of Radiology [Administrative Site] - Philadelphia
- University of Pennsylvania School of Medicine - Philadelphia
- Temple University - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
California
- University of California Los Angeles - Los Angeles
- VA Greater LA Healthcare System - Los Angeles
- Naval Medical Center San Diego - San Diego
Alabama
- University of Alabama, Birmingham - Birmingham
Iowa
- University of Iowa - Iowa City
Maryland
- Walter Reed Army Medical Center - Bethesda
Massachusetts
- VA Boston Healthcare System - Boston
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2026-12 |
What the registry record for NCT04165564 still lists
NCT04165564 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 620-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Institutional standard of care is the first listed.
NCT04165564 lists 19 locations in 14 states (Pennsylvania, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT04165564 about?
NCT04165564 is a clinical study titled "DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers". DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign ind...
What is the current status of trial NCT04165564?
This trial is currently active not recruiting. The enrollment target is 85 participants. The study started on 2020-08-24. Estimated completion is 2026-12.
What conditions does trial NCT04165564 study?
This clinical trial studies the following conditions: Pulmonary Disease.
What interventions are being tested in trial NCT04165564?
The interventions under investigation include: Institutional standard of care (OTHER), Biosamples of airway and blood (OTHER).
Who is sponsoring clinical trial NCT04165564?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04165564 being conducted?
This trial has 19 study locations across Alabama, California, Iowa, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04165564's enrollment target sits among peer trials
85 14th of 19 higher than 6 of 19 other Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections
RECRUITING
-
Quantitative Pulmonary Imaging Registry & Biorepository
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Study of Lung Proteins in Patients With Pneumonia
RECRUITING
-
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
RECRUITING
-
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI